Abzena, a U.K.-based pharma services company, appears to be on an acquisition tear of late, saying it plans to buy a second U.S.-based company in as many months.
Roche will close four plants around the world and lay off 1,200 people as it moves to new technology for manufacturing small molecule drugs. It says it will build a late-stage technical development and launch facility in Switzerland for targeted, high-potency drugs.
POPULAR COMMENT THREADS
South Africa-based Ascendis Health has acquired a 23,000-square-foot manufacturing facility as part of its $24.6 million deal for the pharmaceutical business of Akacia Healthcare.
India's Mankind Pharma earlier this year said it would invest $16 million in an API plant. Now it intends to invest another $30 million to add two more plants in India.
GE Healthcare, which has been on an expansion binge, intends to double its manufacturing capacity for medical imaging contrast media at its plant in Carrigtwohill, Cork, Ireland, with a $40 million expansion.
Sweden's Meda last year laid out $3.1 billion to buy Italy's Rottapharm Madaus with plans to beef up its own consumer health and OTC business. It said at the time it could help pay for that deal in part by paring down some of its infrastructure, and the sale of an API business in Spain follows that line of action.
South Korean electronics giant Samsung got into biologics production with the boast that its manufacturing expertise would allow it to produce products at half the cost of Western drugmakers. It is backing that up with plans for a new plant it says will make it the largest biologics contract manufacturer in the world.
When Dr. Reddy's acknowledged last month that it had received a warning letter for three of its Indian plants, it proclaimed it was "actively engaged" with the FDA to resolve the issues. But an FDA warning letter posted last week says that even after the company responded 9 times to the host of observations, the agency has not been assured it is on top of serious problems which included the discovery of a previously undisclosed testing lab.
From Our Sister Sites
Researchers from the University of California, San Diego have developed technology to isolate drug-delivery nanoparticles from blood.
A month after taking a severe beating at the hands of disappointed investors, Repros Therapeutics has confirmed what company execs had already hinted at: The FDA has rejected its long-delayed testosterone therapy after regulators determined that the agency would need to see data from a new Phase III study before it could determine if the treatment is worth a green light.